9月10日，Moderna盘中下跌3.52%，报132.6美元/股，成交额1.54亿美元，连续三个交易日走弱。
消息面上，生物科技板块整体延续疲弱，安进跌0.17%，百济神州跌2.28%，行业抛压持续。此前Rothschild & Co Redburn将Moderna评级从中性下调至卖出，目标价调整为81美元；瑞银则给予中性评级及150美元目标价，指出近期有三项个体化新抗原疗法数据读出作为潜在催化剂。Moderna此前因mRNA癌症疫苗三期数据利好曾大幅飙升，近期股价持续回调，反映市场对短期涨幅的消化及后续临床推进节奏的重新定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.